The purpose of this paper was to determine if inclusion of a protease inhibitor cocktail or individual protease inhibitors impacts analysis of citrated plasma proteins by 2DE and MALDI-TOF mass spectrometry.
Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry.
Schuchard MD, Mehigh RJ, Cockrill SL, Lipscomb GT, Stephan JD, Wildsmith J, Valdes-Camin R, Kappel WK, Rai AJ, Scott GB
Purpose
Conclusion
Citrate plasma treated with a protease inhibitor cocktail displayed several altered isoform profiles compared to water-treated controls, including the presence of a new high isoelectric point (pI) isoform and altered abundances of low and high pI isoforms. Each of the 6 protease inhibitors present in the cocktail was evaluated individually and the serine protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF) was determined to be responsible for the modified isoform profiles. The proteins affected by inclusion of AEBSF alone or in the protease inhibitor cocktail were identified as apo A1, apo A2, the alpha and beta subunits of haptoglobin, transthyretin, and fibrinogen. Although data was only shown for citrated plasma, the authors report similar results were obtained with serum and EDTA-treated and heparin-treated plasma.
Studies (1)
Purpose
The purpose of this study was to determine if inclusion of a protease inhibitor cocktail or individual protease inhibitors impacts analysis of citrate plasma proteins by 2DE and MALDI-TOF mass spectrometry. The effects of protease inhibitors on the profile of serum and EDTA or heparin plasma were also discussed. Pooled plasma samples containing citrate, EDTA or heparin were obtained from the Human Proteome Organization-Plasma Proteome Project (HUPO-PPP) pilot phase study. Plasma specimens were treated immediately upon thawing with a protease inhibitor cocktail, individual protease inhibitors (AEBSF, aprotinin, leupeptin, bestain, peptatin, or E64) dissolved in DMSO, or water. Water and protease inhibitor treated samples were then depleted for albumin and immunoglobulin G (IgG) and were reduced and alkylated prior to analysis by 2-DE gel and MALDI-TOF mass spectrometry.
Summary of Findings
Citrate plasma treated with a protease inhibitor cocktail displayed altered isoform profiles compared to water-treated plasma. Compared to plasma treated with water, specimens treated with the protease inhibitor cocktail displayed an additional peptide isoform with a high isoelectric point (pI), as well as high pI isoforms of greater intensity, and low pI isoforms of lower intensity. Each of the 6 protease inhibitors present in the cocktail were evaluated individually, and the serine protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF) was determined to be responsible for the modified isoform profiles. Although data was only shown for citrated plasma, the authors report similar results were obtained with serum and EDTA-treated and heparin-treated plasma. While 7 affected 2DE spots were all identified by Western blot and MALDI-TOF mass spectrometry to be apo A1, apo A2, the alpha and beta subunits of haptoglobin, transthyretin, and fibrinogen were also revealed to be affected by the protease inhibitor AEBSF during analysis using the anti-apo A1 antibody.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
Not specifiedPlatforms
Peptide1D/2D gelsPeptideMALDI-TOF MSProteinWestern blotPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant CitrateEDTAHeparinBiospecimen Aliquots and Components Blood and blood products PlasmaSerumAnalyte Extraction and Purification Protease inhibitor 4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF)AprotininBestatinCocktailE-64LeupeptinNo protease inhibitor addedPepstatin